Decision Support in Maryland

Welldoc is a digital health platform company specializing in AI-driven chronic disease management, with a focus on diabetes, hypertension, heart failure, obesity, and behavioral health. Founded in 2005 by an endocrinologist, Welldoc delivers clinically-validated, evidence-based solutions that integrate personalized, real-time insights into patient workflows. The flagship product, BlueStar® (FDA-cleared prescription digital therapeutic), provides automated patient coaching and real-time guidance for adults with type 2 diabetes. Welldoc's platform enables "care anywhere" delivery models for health plans, healthcare systems, and employers, integrating disparate health data into actionable clinical insights across the cardiometabolic spectrum. The company collaborates with major partners including Abbott, CVS Health, Eli Lilly, Dexcom, and others, leveraging data science and behavioral algorithms to improve medication adherence, lifestyle change, and self-management outcomes.

Analytics for Life Inc. develops the CorVista® System, a cloud-based, AI-powered point-of-care diagnostic platform for non-invasive detection of cardiovascular diseases, including coronary artery disease (CAD) and pulmonary hypertension (PH). The proprietary system acquires cardiac and hemodynamic waveform signals at the point of care and transmits them securely to a cloud platform for real-time analysis using machine-learned diagnostic models derived from over 3,300 physiological features. The analytical engine was developed from prospective clinical studies on 10,000+ patients and is supported by over 80 issued patents and 81 pending across 40 invention families. The system provides results within minutes without specialized personnel, contrast agents, or stress testing, enabling physicians to diagnose and direct patient care efficiently while reducing diagnostic delays and loss-to-follow-up. Designed for integration into any professional healthcare setting with WiFi or cellular access, CorVista addresses multiple cardiovascular disease assessments in a single test. The company's regulatory strategy and quality framework are led by experienced personnel with expertise in US, EU, and international medical device submissions. The platform leverages distributed high-compute elastic cloud infrastructure with secure, HIPAA-compliant system design.

BrainScope is a commercial-stage medical neurotechnology company specializing in AI-powered EEG-based diagnostic solutions for brain health. Founded in 2006 and based in Rockville, Maryland, BrainScope has developed a proprietary platform that applies machine learning and computational neuroscience to transform brain electrical activity (EEG) into objective clinical biomarkers. The company created the first FDA-cleared AI/Machine Learning medical device in neurology and holds a portfolio of 83 issued patents. BrainScope's primary offering is a hand-held, point-of-care device for assessing mild traumatic brain injuries (mTBI), structural brain bleeds, and concussions in under 20 minutes. The technology has demonstrated ~50% reduction in unnecessary head CT scans and substantial reductions in emergency department patient length of stay. Beyond head injury assessment, BrainScope is developing novel biomarkers for stroke detection, early Alzheimer's detection (with dementia risk prediction up to 7 years before initial diagnosis), and other CNS indications. The company serves acute care settings, hospitals, emergency departments, and pharmaceutical/drug development partners.

AnthroTronix is an award-winning research and development company specializing in human-centered technology and human-computer interface design. The company develops innovative software and hardware solutions for mobile computing platforms and robotic systems, with particular expertise in cognitive assessment, therapeutic interventions, surgical simulation, and military training applications. AnthroTronix provides advanced product development and R&D services to commercial and governmental sector clients, with deep capabilities in multimodal interfaces, haptic feedback devices, human factors evaluation, and experimental design. The company's interdisciplinary team of engineers, scientists, and designers focuses on optimizing human-technology interaction across health, communication, education, and defense domains.

Mentaily Inc. develops LIV, a generative AI-powered clinical decision support platform designed to revolutionize mental health care delivery. The proprietary system automates and accelerates patient intake, psychiatric triage, screening, and diagnosis using a large language model (LLM) trained to achieve near-perfect accuracy against DSM-5 diagnostic standards. LIV generates instant, precise clinical summaries that replace traditional manual intake processes, enabling clinicians to make faster, more informed treatment decisions while personalizing care plans for individual patients. The platform addresses critical workforce shortages and patient access gaps in behavioral health by increasing clinician throughput without compromising diagnostic accuracy. Mentaily's system has been validated through clinical studies and partnerships with leading institutions including Sheba Medical Center's Innovation Center for Mental Health, Microsoft Global, and KPMG. The platform is currently deployed in medical centers and government health systems. Mentaily maintains HIPAA compliance, ISO 27001 certification for information security, and ISO 13485:2016 medical device quality management certification. The company targets mental health clinics, hospital psychiatry departments, government health agencies, and integrated care networks seeking to reduce wait times, improve diagnostic consistency, and scale mental health capacity.